Highlights Orexo AB OTC Markets

Equities

ORXO.Y

US68616W1027

Market Closed - OTC Markets Other stock markets 10:00:30 2024-05-06 am EDT			5-day change	1st Jan Change
1.65 ^USD	+17.86%		0.00%	+9.27%

May. 08	Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024
Apr. 17	Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment	Apr. 17	MT
Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US	Apr. 17	CI
Sweden's Orexo Set for Early Redemption of Bonds Due 2025	Apr. 02	MT
Orexo Issues SEK500 Million Social Bonds, Closes Tender Offer	Mar. 14	MT
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination	Feb. 12	MT
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox	Feb. 12	CI
Orexo AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Orexo AB Announces FDA Acceptance of New Drug Application Filing for OX124	Nov. 28	CI
Orexo AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Orexo AB Announces Data from the MODIA Study Evaluating Impact on Use of Illicit Opioids	23-10-11	CI
Orexo Files New US Drug Application for Opioid Overdose Medication	23-09-18	MT
Orexo AB (publ.) Submits New Drug Application to FDA for OX124, a High-Dose Rescue Medication for Opioid Over Overio Overio Overio Overio	23-09-18	CI
Orexo Obtains First US Patent for Nasal Epinephrine Product	23-08-29	MT
Orexo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-18	CI
US Court Confirms Validity of Orexo's Patents for Opioid Use Treatment Tablets	23-07-03	MT
Orexo AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Orexo AB (publ.) Shares New Timeline for the High-Dose Rescue Medication for Opioid Overdose, OX124	23-04-03	CI
Orexo AB Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose	23-02-03	CI
Orexo AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-01-26	CI
Orexo AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-01-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Orexo AB OTC Markets

Equities

ORXO.Y

US68616W1027

Highlights

Filters